Accueil   Diary - News   All news ERYTECH reported full GRASPA® PHASE III results

ERYTECH reported full GRASPA® PHASE III results

ERYTECH reported full GRASPA® PHASE III in all and provided update on AML PHASE IIB at ASCO

 

ERYTECH Pharma (the French biopharmaceutical company that develops innovative ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs, reported complete Phase III results of its pivotal program withGRASPA® in Acute Lymphoblastic Leukemia (ALL) and presented the design of the ongoing Phase IIb study in Acute Myeloid Leukemia (AML) at the 51st Annual Meeting of the American Society of Clinical Oncology (ASCO). During an investigator meeting ERYTECH also presented the progress and plans on other development programs.

 

Read the press release 

 

ERYTECH NEWSLETTER

 

 

 

 

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree